Array-CGH predicts prognosis in plasma cell post-transplantation lymphoproliferative disorders

Area of Science:

• Hematology
• Oncology
• Transplantation Immunology

Background:

• Plasma-cell post-transplantation lymphoproliferative disorder (PC-PTLD) is a rare entity with limited cytogenetic data.
• PC-PTLD is subcategorized into plasma cell myeloma (PCM) and plasmacytoma-like lesion (PLL) PTLD.
• Understanding the genetic landscape of PC-PTLD is crucial for diagnosis and prognosis.

Purpose of the Study:

• To comprehensively analyze cytogenetic abnormalities in PC-PTLD using array-based comparative genomic hybridization (aCGH).
• To correlate cytogenetic findings with clinical outcomes, including overall survival (OS).
• To determine the prognostic significance of aCGH in patients with PCM and PLL-PTLD.

Main Methods:

• Array-based comparative genomic hybridization (aCGH) was performed on 10 cases of PC-PTLD (6 PLL, 3 PCM).
• Cytogenetic data were analyzed in conjunction with patient demographics, transplant type, EBV association, treatment, and follow-up.
• Univariate prognostic analysis was conducted to assess the impact of cytogenetic abnormalities on OS.

Main Results:

• Five out of ten PC-PTLD cases exhibited complex cytogenetic profiles.
• The most frequent chromosomal abnormalities included +7q, +16q, +17q, +17p, +5q, t7, t9, and del1p.
• A complex aCGH profile was significantly associated with shorter overall survival (OS).

Conclusions:

• Cytogenetic abnormalities in PC-PTLD share similarities with those found in multiple myeloma and diffuse large B-cell lymphoma.
• Complex aCGH is identified as an unfavorable prognostic marker in PC-PTLD.
• aCGH analysis should be incorporated into the routine evaluation of patients diagnosed with PLL/PCM-PTLD to guide treatment and predict outcomes.